PA
CSTM icon

PharVision Advisers’s Constellium CSTM Stock Holding History

PharVision Advisers’s Portfolio CSTM Stock Details CSTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,466
Closed -$461K – 234
2025
Q4 		$461K Sell
24,466
-9,427
-28% -$156K 0.23% 60
2025
Q3 		$504K Buy
33,893
+22,838
+207% +$327K 0.28% 24
2025
Q2 		$147K Buy
+11,055
New +$124K 0.21% 233
2025
Q1 		– Sell
-16,389
Closed -$168K – 323
2024
Q4 		$168K Buy
+16,389
New +$202K 0.14% 336

Other funds holding CSTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PharVision Advisers's CSTM Position: Q1 2026 in Review

PharVision Advisers sold out of Constellium (CSTM) in Q1 2026, closing a stake of 24,466 shares — an estimated $461K sold.

PharVision Advisers first reported a position in CSTM in Q4 2024 and held it in 4 quarters. The position peaked at $504K in Q3 2025. 313 funds tracked by Wall St. Rank hold CSTM as of Q1 2026.

  • PharVision Advisers reported no remaining Constellium position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 24,466 Constellium shares in Q1 2026, an estimated $461K.
  • PharVision Advisers first reported a position in Constellium in Q4 2024 and held it in 4 quarters.
  • PharVision Advisers's Constellium position peaked at $504K in Q3 2025.
  • 313 funds tracked by Wall St. Rank held Constellium as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.